Immuron (IMRN) Long-Term Investments (2022 - 2023)
Immuron's quarterly Long-Term Investments came in at $1590.7 in Q4 2023, down 49.08% year-on-year from $3123.8 in Q4 2022, and down 98.47% quarter-over-quarter from $104264.5 in Q3 2023.
Immuron has reported Long-Term Investments for 2 years, with the latest figure at $1590.7 in Q4 2023.
- For the quarter ending Q4 2023, Long-Term Investments fell 49.08% year-over-year to $1590.7; the trailing twelve-month figure through Dec 2023 stood at $1590.7 (down 49.08% YoY), and the FY2023 full-year result was $1590.7, down 49.08% from the prior year.
- Long-Term Investments for Q4 2023 stood at $1590.7, down from $104264.5 in the prior quarter.
- The five-year high for Long-Term Investments was $106313.4 in Q2 2023, with the low at $1590.7 in Q3 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 505,194.89 |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.75 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 9.79 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 22.17 Mn |
| 10 | Immuron | 1.27 Bn | 1.27 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 1,590.66 |
| Sep 28, 2023 | 104,264.55 |
| Aug 30, 2023 | 1,590.66 |
| Jun 30, 2023 | 106,313.42 |
| Dec 31, 2022 | 3,123.81 |